POLATUZUMAB AND THE PROGRESSION‐FREE SURVIVAL (PFS) PREDICAMENT: A COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENT AGENCY (HTA) REVIEWS
Bibliographic record
Abstract
As more cancer drugs are approved based on changes in surrogate measures such as PFS, greater controversy surrounds their clinical benefit and economic value. In the POLARIX trial for untreated diffuse large B cell lymphoma (DLBCL), polatuzumab (Polivy), as part of the PolaRCHP regimen, achieved superior PFS than RCHOP (76.7% vs. 70.2%) with no difference in overall survival (OS) – challenging the 20-year standard of care. We examined reviews of PolaRCHP by international HTAs to understand how international expert organizations view a new cancer drug that marginally improves PFS without OS benefit. Methods: We searched NAVLIN (Eversana, Milwaukee, WI), a global HTA database, to determine which HTA organizations have reviewed polatuzumab in untreated DLBCL. We then extracted key summary documents from each group’s website to investigate the rationale provided. Results: Among 14 HTAs that reviewed pola, 5 assessed its use in frontline DLBCL. HTAs in Germany and the UK recommended reimbursement, while those in France and Australia did not. The UK was willing to tolerate an uncertain impact on OS due to acceptable cost effectiveness, while a “hint” of non-quantifiable benefit was sufficient to earn reimbursement in Germany (Table). Conversely, Australia and France emphasized that unchanged overall and complete response rate undermined the PFS benefit (suggesting that PolaRCHP may neither achieve more responses nor deeper responses among responders), as well as the uncertain impact on OS, given the aggressive nature of DLBCL. HTAs considered price differently: the UK found pola’s incremental cost-effectiveness ratio (ICER) acceptable while Australia considered its budget impact too high. France and Germany did not factor price into assessments. Conclusions: Polatuzumab offers insights into how HTAs value PFS: in some countries, a marginal PFS benefit in the absence of OS benefit was sufficient to warrant reimbursement, while other HTAs felt the difference in PFS was undermined by lack of improvement in response rate and depth and OS. Our study is limited by undisclosed negotiated discounts, which may influence reimbursement decisions in different jurisdictions. Understanding how HTAs interpret trial results is essential to ensure optimal design of future clinical trials and improve patient access to effective novel agents. The research was funded by: Arnold Ventures Keywords: aggressive B-cell non-Hodgkin lymphoma, combination therapies Conflicts of interests pertinent to the abstract E. R. S. Cliff Research funding: Arnold Ventures A. J. N. Raymakers Consultant or advisory role Adam Raymakers reports serving as a member of the pan-Canadian Oncology Drug Review Expert Review Committee (pERC) with the Canadian Agency for Drugs and Technologies in Health (CADTH).
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.029 | 0.005 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.004 | 0.000 |
| Bibliometrics | 0.001 | 0.002 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".